Editpep is a CRISPR therapeutics company developing a novel, non-viral delivery platform for peptide-enabled delivery of CRISPR ribonucleoproteins (RNPs) in vivo and ex vivo. The company’s internal pipeline is focused on in vivo CNS programs, leveraging transient, protein-based CRISPR delivery with strong safety and distribution properties in the brain. Editpep’s platform has demonstrated in vivo activity in CNS and additional tissues, enabling potential expansion to ocular, pulmonary, and other indications, including immuno-oncology. In parallel, the platform supports a differentiated ex vivo toolkit for efficient RNP delivery into primary immune cells, including T, B, and NK cells, as well as HSPCs and iPSCs, via partnership-driven models.